• Alda 1: ALDH2 Activator for Cardiac and Radiation Research

  2026-06-02

  Alda 1, a potent ALDH2 activator from APExBIO, offers robust solutions for cardioprotection in ischemia and radiation-induced dermatitis mitigation. This article unpacks experimental workflows and troubleshooting strategies, translating bench findings into actionable protocols for advanced cardiac and aldehyde detoxification research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-06-02

  Oliveira et al. demonstrate that endogenous angiotensin peptides, including Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), selectively enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings reveal a novel cross-talk between the renin–angiotensin system and viral entry pathways, with implications for understanding COVID-19 pathogenesis and developing targeted research models.

• Alda 1: Optimizing ALDH2 Activator Workflows for Cardiac Res

  2026-06-01

  Alda 1 delivers precise ALDH2 activation, uniquely enabling both cardioprotection in ischemia models and mitigation of radiation-induced dermatitis. This article translates breakthrough findings into actionable protocols, troubleshooting strategies, and workflow enhancements for advanced cardiac and aldehyde detoxification research.

• Fosinopril Sodium in Precision Hypertension Research: Pharma

  2026-06-01

  Explore the nuanced pharmacokinetic and mechanistic profile of Fosinopril sodium, a potent ACE inhibitor, and discover its unique advantages for hypertension and cardiovascular disease research. This article delivers deeper analytical guidance on protocol design and model selection for scientists aiming to achieve translational relevance.

• GSH-Responsive Indocyanine Green MOF Nanoplatforms for Melan

  2026-05-31

  This study introduces a glutathione-responsive, indocyanine green-loaded MOF nanoparticle system modified with a PD-1 inhibitory peptide for synergistic photothermal and immunotherapy of melanoma. The approach achieves targeted immune checkpoint blockade and enhanced tumor cell ablation, demonstrating a promising strategy for overcoming limitations of single-modal photothermal therapy.

• MEG3 Regulates PI3K/Akt in NiO Nanoparticle-Induced Lung Fib

  2026-05-30

  This study uncovers a mechanistic link between lncRNA MEG3, TGF-β1, and the PI3K/Akt pathway in nickel oxide nanoparticle-induced pulmonary fibrosis. By demonstrating that MEG3 overexpression and pharmacological inhibition of PI3K can mitigate fibrosis markers, the research highlights actionable targets for understanding and potentially managing nanoparticle-induced lung injury.

• HyperScribe™ Poly (A) Tailing Kit for mRNA Stability Enhance

  2026-05-29

  The HyperScribe™ Poly (A) Tailing Kit empowers researchers to efficiently polyadenylate in vitro transcribed RNA, boosting mRNA stability and translation efficiency for advanced applications. This workflow-driven guide details best practices, troubleshooting strategies, and protocol enhancements rooted in both the reference literature and expert lab experience.

• Escitalopram (SKU B1183): Precision for Serotonergic Assays

  2026-05-29

  This article provides a scenario-driven, evidence-based guide to using Escitalopram (SKU B1183) for reproducible cell viability, proliferation, and cytotoxicity assays. Biomedical researchers and laboratory professionals will find practical insights grounded in validated literature and workflow experience, with APExBIO’s high-purity formulation highlighted for reliability and data integrity.

• Mechanisms of Cell Death in Heart Disease: Regulated Pathway

  2026-05-28

  This article reviews the pivotal findings from 'Mechanisms of Cell Death in Heart Disease,' which distinguishes regulated necrosis from apoptosis and highlights their roles in cardiac pathology. The study's insights underpin current approaches to dissecting cell death mechanisms and inform the use of selective ferroptosis inhibitors in translational research.

• Azilsartan Medoxomil Monopotassium: Network Meta-Analysis Re

  2026-05-28

  A recent systematic review and network meta-analysis provides robust comparative evidence that azilsartan medoxomil (TAK 491) at 80 mg delivers the most effective office blood pressure reduction among first-line antihypertensive agents for mild-to-moderate hypertension. This work enhances our understanding of angiotensin II receptor signaling pathway inhibition and supports refined drug selection in essential hypertension treatment research.

• Deracoxib: Selective COX-2 Inhibitor for Cancer and Inflamma

  2026-05-27

  Deracoxib stands out as a selective COX-2 inhibitor with proven anti-inflammatory and antitumor properties, optimized for reliable pain and inflammation research. Its precise action and robust assay compatibility empower advanced workflows in veterinary oncology and inflammation modeling.

• Sulfo-NHS-Biotin (A8001): Reproducible Cell Surface Labeling

  2026-05-27

  This article delivers an evidence-based, scenario-driven deep dive into Sulfo-NHS-Biotin (SKU A8001), optimizing cell surface protein labeling for assays of viability, proliferation, and cytotoxicity. Designed for biomedical researchers and technicians, it addresses common pain points in reproducibility and specificity, linking protocol choices to reliable outcomes and supporting best practices with recent literature and quantitative details.

• Azilsartan Medoxomil Monopotassium: Redefining Translational

  2026-05-26

  Explore how Azilsartan medoxomil monopotassium (TAK 491) advances hypertension and cardiovascular research through superior AT1 receptor antagonism and translational impact. This article delivers mechanistic insight, critical evidence, and strategic protocol guidance—bridging fundamental discovery with clinical promise for the next generation of blood pressure regulation studies.

• Tankyrase Inhibitors Suppress HCC via Hippo Pathway Modulati

  2026-05-26

  Jia et al. (2017) reveal that selective tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell growth by modulating the Hippo-YAP signaling axis. Their findings connect tankyrase inhibition to reduced YAP activity and highlight potential therapeutic strategies for HCC.

• Fosinopril Sodium: ACE Inhibitor Innovations in Hypertension

  2026-05-25

  Fosinopril sodium stands out as a third-generation ACE inhibitor with unique pharmacokinetic features and robust translational value for hypertension and cardiovascular disease models. This article delivers actionable protocols, advanced troubleshooting, and cross-study insights to help researchers optimize blood pressure and renal hemodynamics experiments using APExBIO’s trusted compound.

451 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page